Pharmaceuticals

FDA approves subcutaneous and intravenous administration of Volz for the treatment of multiple myeloma and mantle cell lymphoma

bexib
By bexib 0 Min Read

Borz is the first ready-to-use version of bortezomib for subcutaneous and intravenous administration in the treatment of multiple myeloma and mantle cell lymphoma.

You Might Also Like

As the Senate turns its attention to patents, a former director of the U.S. Patent and Trademark Office is calling the effort a “big misunderstanding.”

Cleared and Rated: Modernizing the 510(k) Pathway

Talent management strategies for post-milestone growth

Acerylline’s hidradenitis suppurativa treatment Izokibep shows good results

Johnson & Johnson Submits Supplemental New Drug Application to FDA for Spravato as Monotherapy for Adults with Treatment-Resistant Depression

Share This Article
Previous Article Rob Urie: Naked capitalism informs when markets collapse and wars rage
Next Article July new home sales rise to annual rate of 739,000
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Five payment trends in Asia that will shape the financial landscape in 2025
Fintech
BNPL drives growth for suppliers and retailers
Retail & E-commerce
Hotel chef obtains new qualification
Hospitality & Tourism
Print the shirt with 3D James Nobak
Manufacturing